Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mlck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U
These conditions are closely linked to increased cardiovascular risk and long-term health complications
Liraglutide, in combination with metformin, has demonstrated synergistic antipancreatic cancer effects in both in vivo and in vitro studies [8]
Oral formulations will grow to capture 25% share as bioavailability improves and new small-molecule GLP-1s reach the market, appealing to segments seeking greater convenience or avoiding injection-site issues
Animal studies (Neelakantan et al., Biochemical Pharmacology, 2018) showed significant body fat reduction without changes in food intake